ESMO

News

ESMO21: Enhertu brings it’s A game to second-line breast can...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r

News

ESMO21: First combo data with Amgen's Lumakras hit the mark ...

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix

News

ESMO21: Roche's giredestrant takes stage in battle of the or...

Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide an oral alternative to AstraZen

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Immunomedics wows ESMO with breast cancer data reveal

Immunomedics has revealed the trial data that convinced Gilead to stage a

Views & Analysis

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.

News